Oncosnacks 12: Enfortumab Vedotin skin toxicity management

On this episode, their final of 2023, Michael and Josh return to the world of recent fan favourite, enfortumab vedotin (EV). Not content to sing its praises from every rooftop, our intrepid hosts take the necessary step of examining the common and sometimes severe manifestations of dermatological toxicity deriving from EV. With the assistance of a recently published guideline, they examine the presentation, assessment and management of skin toxicity.

From all of us at OftiM, we would like to thank you for joining us throughout 2023, and we wish you a very happy festive season.